About 5% of patients with coronavirus disease 2019 (COVID-19) require intensive care unit (ICU) management.1 These patients are at high risk of developing secondary infections including invasive pulmonary aspergillosis (IPA).2 First reported with H1N1 influenza, IPA represents a frequent (20–30%) and early-onset complication (median, 3 days post-ICU admission) in critically ill patients with influenza, leading to enhanced illness severity and mortality (40–60%).3, 4 Most cases have been observed in non-immunocompromised patients, questioning the applicability of the European Organization for Research and Treatment of Cancer Mycoses Study Group (EORTC-MSG) consensus criteria used to define aspergillosis in immunocompromised patients.5 Therefore, an algorithm to discriminate Aspergillus spp colonisation from putative IPA was developed for patients in ICU on the basis of mycological criteria combining culture from respiratory specimens and galactomannan detection in the bronchoalveolar lavage (BAL) and serum.4, 6